SCHEMBL16750106

SCHEMBL16750106

CC(C)C(=O)N1CCN(C)C(=O)C1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.46
P2RX7 Q99572 6/20 0.44
DPP4 P27487 1/20 0.44
POLB P06746 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
CHRNB2 P17787 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNB3 Q05901 1/20 0.36
CHRNA6 Q15825 1/20 0.36
KDM1A O60341 1/20 0.35
TGM2 P21980 1/20 0.35
CECR2 Q9BXF3 1/20 0.34
BRD4 O60885 1/20 0.34
BRD2 P25440 1/20 0.34
NPC1 O15118 1/20 0.34
NAMPT P43490 1/20 0.34
MET P08581 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10274984 0.87 PIK3CD (0.44) PIK3CDP2RX7DPP4KDM1ACECR2
SCHEMBL19473330 0.79 CHRNB2 (0.35) POLBRXFP1CHRNB2CHRNA3CHRNA4
SCHEMBL10274994 0.78 CYP1A2 (0.48) PIK3CDP2RX7DPP4CECR2BRD4
SCHEMBL5508211 0.78 P2RX7 (0.47) PIK3CDP2RX7DPP4CECR2BRD4
SCHEMBL23153416 0.76 P2RX7 (0.46) PIK3CDP2RX7DPP4CECR2BRD4
SCHEMBL6948066 0.76 P2RX7 (0.46) PIK3CDP2RX7DPP4CECR2BRD4
SCHEMBL11187153 0.76 P2RX7 (0.50) PIK3CDP2RX7DPP4POLBKDM1A
SCHEMBL4546617 0.73 CHRNB2 (0.50) PIK3CDPOLBRXFP1CHRNB2CHRNA3
SCHEMBL22753493 0.73 CHRNB2 (0.50) PIK3CDPOLBRXFP1CHRNB2CHRNA3
SCHEMBL674660 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530193-B2 Kinase inhibitors THE UNIVERSITY OF MANCHESTER (GB) 2022-12-20 US disclosed
EP-3189048-B1 AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS CTXT PTY LTD (AU) 2021-03-17 EP disclosed
US-10421743-B2 Tetrahydroisoquinolines as PRMT5 inhibitors CTXT PTY LTD (AU) 2019-09-24 US disclosed
US-20190071425-A1 TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS CTXT PTY LTD (AU) 2019-03-07 US disclosed
US-10005792-B2 Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors CTXT PTY. LTD. (AU) 2018-06-26 US disclosed
US-20170313713-A1 AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS CTXT PTY. LTD. (AU) 2017-11-02 US disclosed
US-20170283407-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY. LTD. (AU) 2017-10-05 US disclosed
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-05 US disclosed
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-05 US disclosed
US-9376418-B2 Substituted pyridine spleen tyrosine kinase (SYK) inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-28 US disclosed
US-20150148327-A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK CANADA INC. (CA) 2015-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005792-B2 Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors PRMT5, PRMT1, PRMT3 PIK3CD 2878/4885P2RX7 4783/4885DPP4 4165/4885
US-20170313713-A1 AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS PRMT5, PRMT1, PRMT3 PIK3CD 2886/4885P2RX7 4762/4885DPP4 4161/4885
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PIK3CD 3639/4885P2RX7 4779/4885DPP4 1543/4885
US-20190071425-A1 TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 PIK3CD 1638/4885P2RX7 4623/4885DPP4 3734/4885
US-11530193-B2 Kinase inhibitors CAMKK2, CAMK1, CAMKK1 PIK3CD 443/4885P2RX7 2642/4885DPP4 1297/4885
US-10421743-B2 Tetrahydroisoquinolines as PRMT5 inhibitors PRMT5, PRMT1, PRMT3 PIK3CD 1638/4885P2RX7 4623/4885DPP4 3734/4885
US-20170283407-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS PRMT5, PRMT3, PRMT1 PIK3CD 2359/4885P2RX7 4694/4885DPP4 4170/4885
US-20150148327-A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS SYK, BTK, LYN PIK3CD 454/4885P2RX7 317/4885DPP4 3633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.